EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis

Laleh Khodadadi, Deborah Puppe, Dilara S Cirillo, Carolina Martinez-Cingolani, Jens Klotsche, Andreas Pelz, Siegfried Kohler, Qingyu Cheng iD, Konstantinos Lazaridis, Michael Fichtner, Jan Pille, Andrey Kruglov iD und 5 weitere

European Journal of Immunology · 2026

DOI: 10.1002/eji.70166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2026. Verfasst von Laleh Khodadadi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-U…. Hauptthemen laut MEDLINE: Autoantibodies, Plasma Cells, Myasthenia Gravis, Receptors, Nicotinic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Leibniz-Gemeinschaft, Sanofi France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is a chronic autoimmune disease mediated by autoantibodies targeting the neuromuscular junction and leading to muscle weakness. Although there are autoantibodies of different specificities, most MG patients have autoantibodies directed against the nicotinic acetylcholine receptor (AChR), in particular against the extracellular domain of the α1 subunit (αECD), containing the main immunogenic region (MIR). Here, we demonstrate an original approach to selectively deplete plasma cells secreting autoantibodies targeting αECD. An antibody‐mediated cytotoxicity‐engager (ACE) consisting of an anti‐hCD38‐antibody conjugated to hAChR αECD (αECD) was used to deplete hAChR αECD‐specific cells selectively in vivo. The reduction of pathogenic cells was accompanied by lower antibody titers, a reduction of MG disease score, protection of grip strength, and maintenance of body weight. Notably, antibody‐secreting cells that are nonspecific for hAChR αECD were not affected. The resulting amelioration of MG pathology in ACE‐treated animals highlights the decisive role of αECD‐antibodies in the pathogenesis of MG and the clinical relevance of the novel therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesPlasma CellsMyasthenia GravisReceptors, NicotinicReceptors, CholinergicMyasthenia Gravis, Autoimmune, ExperimentalAnimalsHumansMiceFemaleAntibody-Dependent Cell Cytotoxicity

Stichwörter der Autor:innen

autoimmunityautoreactive plasma cellsmyasthenia gravisselective depletion

Substanzen

AutoantibodiesReceptors, NicotinicReceptors, Cholinergic

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • German Rheumatology Research Center (DRFZ), Leibniz Institute, Berlin, Germany.
  • Sanofi R&D, Immunology and Inflammation Therapeutic Research Area, Vitry-sur-Seine, France.
  • Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Neurology, Sana Klinik Biberach, Biberach, Germany.
  • Department of Immunology, Hellenic Pasteur Institute, Athens, Greece.

ORCID-Profile: Qingyu Cheng, Andrey Kruglov, Tobias Alexander, Andreas Radbruch, Falk Hiepe

Förderung

  • Deutsche Forschungsgemeinschaft
  • Leibniz-Gemeinschaft
  • Sanofi France

Zitieren

APA

Khodadadi, L., Puppe, D., Cirillo, D. S., Martinez-Cingolani, C., Klotsche, J., Pelz, A., Kohler, S., Cheng, Q., Lazaridis, K., Fichtner, M., Pille, J., Kruglov, A., Bondareva, M., Alexander, T., Radbruch, A., Meisel, A., & Hiepe, F. (2026). Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis. European Journal of Immunology. https://doi.org/10.1002/eji.70166

Vancouver

Khodadadi L, Puppe D, Cirillo DS, Martinez-Cingolani C, Klotsche J, Pelz A, et al. Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis. European Journal of Immunology. 2026. doi:10.1002/eji.70166

BibTeX
@article{Khodadadi2026,
  author = {Khodadadi, Laleh and Puppe, Deborah and Cirillo, Dilara S and Martinez-Cingolani, Carolina and Klotsche, Jens and Pelz, Andreas and Kohler, Siegfried and Cheng, Qingyu and Lazaridis, Konstantinos and Fichtner, Michael and Pille, Jan and Kruglov, Andrey and Bondareva, Marina and Alexander, Tobias and Radbruch, Andreas and Meisel, Andreas and Hiepe, Falk},
  title = {Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis},
  journal = {European Journal of Immunology},
  year = {2026},
  doi = {10.1002/eji.70166}
}
Kostenlos starten →